Drug treatment options for acute promyelocytic leukemia

References

• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cicconi L. History of acute promyelocytic leukemia: a tale of endless revolution. Mediterr J Hematol Infect Dis. 2011;3(1):e2011067.
   PubMedGoogle Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–1643.
   PubMed Web of Science ®Google Scholar
• Breccia M, Lo Coco F. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res. 2014 May;133(Suppl 2):S112–6.
   PubMedGoogle Scholar
• Gurnari C, Breccia M, Di Giuliano F, et al. Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. Br J Haematol. 2021;193(1):129–132.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Lo-Coco F. Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol. 2016;27(8):1474–1481.
   PubMed Web of Science ®Google Scholar
• Kakizuka A, Miller WH, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66(4):663–674.
   PubMed Web of Science ®Google Scholar
• Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423–431.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489–496.
   PubMed Web of Science ®Google Scholar
• Cunningham I, Gee TS, Reich LM, et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73(5):1116–1122.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Jarque I, Martin G, et al. Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer. 1988;61(1):7–13.
   PubMed Web of Science ®Google Scholar
• Huang ME, Ye YC, Chen SR, et al., Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72(2): 567–572. 1988.
   PubMed Web of Science ®Google Scholar
• Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980;77(5):2936–2940.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as differentiating therapy for acute promyelocytic leukemias. 1990;76:1704–1709. Clinical Results Blood.
   PubMed Web of Science ®Google Scholar
• Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med. 1991;324(20):1385–1393.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al., Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 116(17): 3171–3179. 2010.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13):4298–4302.
   PubMed Web of Science ®Google Scholar
• Zhang T, Sun H, Hu H. Treatment of acute promyelocytic leukemia with Ail- ing number one combination therapy: a study of 73 cases [Chinese]. 1981;4:40–44. Hei-longjiang J Tradit Chin Med.
   Google Scholar
• Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339(19):1341–1348.
   PubMed Web of Science ®Google Scholar
• Shen Z-X, Shi -Z-Z, Fang J, et al. All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328–5335.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–1253.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al., Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369(2): 111–121. 2013.
   PubMed Web of Science ®Google Scholar
• Burnett A, Russell NH, Hills RK, et al., Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukemia in all risk groups (AML17): results of a randomized, controlled, phase 3 trial. Lancet Oncol. 16(13): 1295–1305. 2015.
   PubMed Web of Science ®Google Scholar
• A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) ClinicalTrials.gov, NCT02688140
   Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 25(7): 1128–1134. 2011.
   PubMed Web of Science ®Google Scholar
• Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129(13):1763–1767.
   PubMed Web of Science ®Google Scholar
• Breccia M, De Propris MS, Minotti C, et al. Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leuk Res. 2014;38(2):194–197.
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica. 2013;98(12):e161–e163.
   PubMed Web of Science ®Google Scholar
• Esnault C, Rahmé R, Rice KL, et al. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood. 2019;133(13):1495–1506.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Mandelli F, Petti MC, et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol. 1990;44(4):257–260.
   PubMed Web of Science ®Google Scholar
• Marty M, Ganem G, Fisher J, et al. Leucémie aiguë promyélocytaire: étude rétrospective de 119 malades traités par daunorubicine. Nouv Rev Fr Hematol. 1984;26:371–378.
   PubMedGoogle Scholar
• Arlin Z, Kempin S, Mertelsmann R, et al. Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. Blood. 1984;63(1):211–212.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Pollet JP, Vandenbossche-Simon L, et al. Treatment of acute promyelocytic leukemia: a report of 70 cases. Leuk Lymphoma. 1991; 4:239–248
   Google Scholar
• Petti MC, Avvisati G, Amadori S, et al. Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica. 1987;72:151–155.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Vernant JP, Brun B, et al. Acute promyeocytic leukemia in 57 previously untreated patients. Cancer. 1985;55(1):18–25.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Keating MJ, Walters RS, et al. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986;80:789–797.
   PubMed Web of Science ®Google Scholar
• Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood. 1995;86(5):1717–1728.
   PubMed Web of Science ®Google Scholar
• Flynn PJ, Miller WJ, Weisdorf DJ, et al. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood. 1983;62(6):1211–1217.
   PubMed Web of Science ®Google Scholar
• Daenen S, Vellenga E, van Dobbenburgh OA, et al. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood. 1986;67(2):559–561.
   PubMed Web of Science ®Google Scholar
• lmaizumi M, Tr B. Retinoic acid-induced differentiation of the human promyelocytic leukemia cell line, HL-60, and fresh human leukemia cells in primary culture: a model for differentiation inducing therapy of leukemia. Eur J Haematol. 1987;38(4):289.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515.
   PubMed Web of Science ®Google Scholar
• Germain P, Iyer J, Zechel C, et al. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002;415(6868):187–192.
   PubMed Web of Science ®Google Scholar
• Orfali N, O’Donovan TR, Nyhan MJ, et al. Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Experimental Hematology. 2015;43(9):781–793.
   PubMed Web of Science ®Google Scholar
• Degos L, Chomienne C, Daniel MT, et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet. 1990;336(8728):1440–1441.
   PubMed Web of Science ®Google Scholar
• Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991;78(6):1413–1419.
   PubMed Web of Science ®Google Scholar
• Warrell RPJ, Maslak P, Eardley A, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia. 1994;8:929–933.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Castaigne S, Dombret H, et al. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood. 1992;80(9):2176–2181.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94:1192–1200.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014–1021.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94(9):3015–3021.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–4725.
   PubMed Web of Science ®Google Scholar
• Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML/RARA transcript after consolidation therapy; the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59–66.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Gonzalèz JD, Gonzalèz J, et al. Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy. J Clin Oncol. 2010;28(24):3872–3879.
   PubMed Web of Science ®Google Scholar
• Vitaliano-Prunier A, Halftermeyer J, Ablain J, et al. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood. 2014;124(25):3772–3780.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhao WL, Shen ZX, et al. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Curr Top Microbiol Immunol. 2007;313:129–144.
   PubMed Web of Science ®Google Scholar
• Ablain J, Rice K, Soilihi H, et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 2014 Feb;20(2):167–174.
   PubMed Web of Science ®Google Scholar
• Gurnari C, De Bellis E, Divona M, et al. When Poisons Cure: the Case of Arsenic in Acute Promyelocytic Leukemia. Chemotherapy. 2019;64(5–6):238–247.
   PubMed Web of Science ®Google Scholar
• Sun HD, Ma L, Hu XC, et al. The clinical report of 16 long-term survivors of acute promyelocytic leukemia treated with Ai-Ling 1 and traditional Chinese medicine. Inf Tradit Chin Med. 1991;06:39–41
   Google Scholar
• Sun HD, Ma L, Hu XC, et al. Treatment of acute promyelocytic leukemia (32 cases) with intravenous arsenic trioxide. 1992;12:170–171. Chin J Integrat Chin West Med.
   Google Scholar
• Zhang P, Wang SY, Hu LH, et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996;2:58–62.
   Google Scholar
• Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic patients. Blood. 1999;94(10):3315–3324.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi KM, et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627–2632.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17(1):131–134.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28(24):3866–3871.
   PubMed Web of Science ®Google Scholar
• Rego EM, He LZ, Warrell RP, et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA. 2000;97(18):10173–10178.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999;189(7):1043–1052.
   PubMed Web of Science ®Google Scholar
• De Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775–783.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–1580.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised Phase 2 trial. Lancet Haematol. 2015;2(9):357–366.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751–3757.
   PubMed Web of Science ®Google Scholar
• Adès L, Thomas X, Guerci Bresler A, et al. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French-Belgian-Swiss APL group. Haematologica. 2018;1:1.
   Google Scholar
• Ravandi F, Estey E, Jones D, et al. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology. 2009;27(4):504–510.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2016;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–1891.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network; Fort Washington, PA, USA: 2015. NCCN guidelines ‘Acute myeloid leukemia,’ version 1.2015
   Google Scholar
• Montesinos P, Diaz-Mediavilla J, Deben G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009;94(9):1242–1249.
   PubMed Web of Science ®Google Scholar
• Seftel MD, Barnett MJ, Couban S, et al. A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults. Curr Oncol. 2014;21(5):234–250.
   PubMed Web of Science ®Google Scholar
• H-h Z, Wu D-P, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–4221.
   PubMed Web of Science ®Google Scholar
• Gill H, Yim R, Lee HKK, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study. Cancer. 2018;124(11):2316–2326.
   PubMed Web of Science ®Google Scholar
• Zhu -H-H, Wu D-P, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871–879.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al., Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 113(4): 775–783. 2009.
   PubMed Web of Science ®Google Scholar
• De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92:2712–2718.
   PubMed Web of Science ®Google Scholar
• Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood. 1997;90(7):2747–2756.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27(16):2668–2676.
   PubMed Web of Science ®Google Scholar
• de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol. 2005;23(1):120–126.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Voso MT, Girardi K, et al. Acute Promyelocytic Leukemia in Children: a Model of Precision Medicine and Chemotherapy-Free Terapia. Int J Mol Sci. 2021;22(2):642.
   Web of Science ®Google Scholar
• Friedman DI, Liu GT, Digre KB. Liu GT and Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013 Sep 24;81(13):1159–1165.
   PubMed Web of Science ®Google Scholar
• Zhu H, Hu J, Chen L, et al. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016;128(11):1525–1528.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Saussele S, Weisser A, et al. Treatment concepts of acute promyelocytic leukemia. Critical Reviews in Oncology/Hematology. 2005;56(2):261–274.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94(7):2225–2229.
   PubMed Web of Science ®Google Scholar
• Esteve J, Escoda L, Martin G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia. 2007;21(3):446–452.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, et al., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 19(18): 3852–3860. 2001.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen XY, Wang BS, et al. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leukemia Research. 2011;35(9):1170–1177.
   PubMed Web of Science ®Google Scholar
• Breccia M, Cicconi L, Minotti C, et al. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. Haematologica. 2011;96(9):1390–1391.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Breccia M, Franceschini L, et al. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Ann Hematol. 2018;97(10):1797–1802.
   PubMed Web of Science ®Google Scholar
• Langfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26(3):433–442.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Lo-Coco F, Ades L, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia. 2015;29(5):1084–1091.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Mathews V, Alimoghaddam K, et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2. Bone Marrow Transplantation. 2016;51(9):1180–1183.
   PubMed Web of Science ®Google Scholar
• Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biology of Blood and Marrow Transplantation. 2014;20(7):1021–1025.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Ottone T, Alfonso V, et al. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. Am J Hematol. 2019 Oct;94(10):1091–1097.
   PubMed Web of Science ®Google Scholar